surmount-1 trial tirzepatide non-diabetic obesity weight loss Yields Top of 20% or More in SURMOUNT Clinical 𝗠𝗼𝘀𝘁 𝗽𝗲𝗼𝗽𝗹𝗲 𝗮𝘀𝘀𝘂𝗺𝗲 𝘁𝗵𝗲 𝘄𝗲𝗶𝗴𝗵𝘁

Despite increased investments by Lilly and Novo to boost production, shortages continue, especially for the lower starter doses of Wegovy, which the FDA still lists as being in shortage

GHK-Cu: The Copper Peptide Component GHK-Cu is a copper-binding tripeptide with antioxidant properties composed of glycyl-L-histidyl-L-lysine

Over a 4.5-year period, an estimated 847,598 MACE would occur in the absence of treatment with oral semaglutide, compared with 728,934 events with treatmentcorresponding to 118,664 events potentially prevented (14%), with a number needed to treat (NNT) of 55 (Table 2)

Common reasons your GLP-1 is not working If youve been on a GLP-1 medication for months without seeing meaningful changes in your health or significant weight loss, youre likely wondering whats going on

This paper by Stefania Glieca et al, investigates an inhalable semaglutide formulation as a promising alternative to subcutaneous delivery, demonstrating rapid pulmonary absorption and favorable pharmacokinetic performance in preclinical models